Clinical Trial

A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
A two-center, randomized, double-blind, placebo-controlled, dose-escalation IIT clinical study evaluating the safety and preliminary efficacy of injectable IMC-001 in improving atherosclerotic plaque stability in patients with acute coronary syndrome. The plan is to conduct 2 dose groups, with 9 subjects enrolled in each group, including 6 in the treatment group and 3 in the control group. The treatment group will receive IMC-001 along with optimal drug therapy, with a total of 12 subjects included, while the control group will receive a placebo along with optimal drug therapy, with a total of 6 subjects included.
Protocol Amendment History 1 change
critical Phase changed: Phase 2 -> Early Phase 1 2026-04-16
Trial Details
NCT Number NCT06788431
Lead Sponsor ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Collaborators: RenJi Hospital, ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd., First Affiliated Hospital of Nanyang Medical College
Conditions Atherosclerosis
Enrollment 18 participants
Start Date 2025-03-10
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-15